Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

(2018) Claire A. Martin et al.   INTERNATIONAL JOURNAL OF CANCER

Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing

(2018) Sarah V. Gerhart et al.   Scientific Reports

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

(2018) Anusha Sriraman et al.   Cell Death & Disease

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

Arginine Methylation: The Coming of Age

(2017) Roméo S. Blanc et al.   MOLECULAR CELL

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

(2017) Xiangjun Kong et al.   NATURE

Targeting MDM4 Splicing in Cancers

(2017) Boris Bardot et al.   Genes

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma

(2016) Jessica L.F. Teh et al.   CANCER RESEARCH

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6

(2016) A. Yoshida et al.   CANCER RESEARCH

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

(2016) Konstantinos J. Mavrakis et al.   SCIENCE

MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

(2016) Gregory V. Kryukov et al.   SCIENCE

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

(2016) Katya Marjon et al.   Cell Reports

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

(2015) Nicole Stopa et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

(2015) M. E. Olanich et al.   CLINICAL CANCER RESEARCH

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

(2015) T. MAHGOUB et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers

(2015) Vipin Yadav et al.   PHARMACOLOGY & THERAPEUTICS

Targeting Mdmx to treat breast cancers with wild-type p53

(2015) S Haupt et al.   Cell Death & Disease

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

(2014) Y.-X. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

(2013) Y. Liao et al.   BIOINFORMATICS

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

(2013) K. E. Sheppard et al.   CLINICAL CANCER RESEARCH

Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery

(2013) M. Bezzi et al.   GENES & DEVELOPMENT

Structure of the Arginine Methyltransferase PRMT5-MEP50 Reveals a Mechanism for Substrate Specificity

(2013) Meng-Chiao Ho et al.   PLoS One

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

Mdm2 and MdmX partner to regulate p53

(2012) Xinjiang Wang et al.   FEBS LETTERS

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

Crystal structure of the human PRMT5:MEP50 complex

(2012) S. Antonysamy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Versatility of PRMT5-induced methylation in growth control and development

(2011) Vrajesh Karkhanis et al.   TRENDS IN BIOCHEMICAL SCIENCES

Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase

(2010) Priya Aggarwal et al.   CANCER CELL

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats

(2008) M. J. Herold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA